ORGO 13D/A: Insiders Control 76.4M Shares, Top Holder at 17.6%
Organogenesis Holdings Inc. (ORGO) – Schedule 13D/A (Amendment 10) filed 06/24/2025 The filing updates beneficial ownership information for a long-standing reporting group comprised of company founders, related trusts and affiliated investment vehicles.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Organogenesis Holdings Inc. (ORGO) – Schedule 13D/A (Amendment 10) filed 06/24/2025
The filing updates beneficial ownership information for a long-standing reporting group comprised of company founders, related trusts and affiliated investment vehicles. No purchase or sale prices are disclosed in the excerpt; however, the cover page states that the amendment was triggered by an event on June 24 2025.
Key ownership positions disclosed
- Alan A. Ades: 22,319,836 shares (17.6% of Class A common), of which 11.2 million are held with sole voting/dispositive power and 11.1 million with shared power.
- Albert Erani: 17,920,498 shares (14.1%) – approximately 6.8 million sole and 11.1 million shared.
- Glenn H. Nussdorf: 11,912,841 shares (9.4%) – 11.0 million sole, 0.9 million shared.
- Dennis Erani: 10,043,701 shares (7.9%) – 1.3 million sole, 8.7 million shared.
- Organo PFG LLC: 8,279,490 shares (6.5%) – all sole voting/dispositive.
- Other entities & individuals: Organo Investors LLC (2.9 million / 2.2%), Alan Ades 2014 GRAT (3.1 million / 2.4%) and Starr Wisdom (20,000 / <0.1%).
Based on the amounts reported, the group collectively controls approximately 76.4 million Class A shares. Although total shares outstanding are not provided in the excerpt, each of the first four individuals continues to exceed the 5% reporting threshold, indicating significant insider alignment with shareholders. The amendment does not specify whether positions increased or decreased relative to the prior filing.
No financial performance metrics, transaction prices or strategic commentary accompany the ownership data, suggesting that the filing is largely administrative—updating share counts and voting arrangements among a pre-existing insider group.
Insights
TL;DR: Filing updates insider group holdings; no strategic shift or price data—neutral governance disclosure.
This tenth amendment to the Schedule 13D re-states the stakes of key founders and affiliated entities in Organogenesis Holdings. The largest holder, Alan A. Ades, retains 17.6% of the float, while three other insiders each remain above 5%. Combined, the group reports 76.4 million shares, reinforcing concentrated ownership but providing no indication of fresh accumulation or planned corporate action. Because neither changes in percentage ownership nor intentions (Item 4) appear in the excerpt, I view the disclosure as routine and not materially catalytic for the share price in the short term. Investors may take comfort in sustained insider alignment, yet the absence of new initiatives or purchases limits immediate market impact.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What event date triggered this Schedule 13D/A filing for ORGO?
Does Albert Erani remain a 5%+ beneficial owner of Organogenesis?
AI-generated analysis. How Rhea-AI works. Not financial advice.